Alerta

SYSTEMS, DEVICES, AND METHODS FOR WELLNESS MONITORING WITH PHYSIOLOGICAL SENSORS

Absstract of: US2025221639A1

Systems and methods for monitoring glucose levels of a user are described. Data indicative of glucose levels of the subject is received. A count is assigned for each glucose episode based at least on an area under the curve of the each glucose episode in a dataset of time-correlated glucose data. A running sum of counts for each glucose episode in a time period is calculated. The running sum of the counts may be displayed in a numerator of a fraction and a target count goal in a denominator of the fraction. A progress indicator representative of the running sum of the counts relative to a target count goal for the time period may also be displayed. A length of a variable portion may be proportional to the running sum of the counts, and a total length of the progress indicator may be proportional to the target count goal.

Systems and Methods for Predictive Glucose Management

Absstract of: US2025221673A1

Systems and methods for predictive glucose in accordance with embodiments of the invention are illustrated. One embodiment includes glucose management device, including a brain signal recorder, and a controller, including a processor, and a memory, the memory containing a glucose monitoring application configured to direct the processor to record a brain activity signal of a user's brain using the brain signal recorder, and decode the brain activity signal to predict future glucose levels of the patient.

ARTIFICIAL INTELLIGENCE-BASED APPARATUS AND METHOD FOR PANCREATIC FROZEN SECTION EXAMINATION AND DIAGNOSIS

Absstract of: WO2025147163A1

The present disclosure relates to an artificial intelligence-based apparatus and method for pancreatic frozen section examination and diagnosis. The apparatus comprises: a memory; and a processor including an artificial intelligence engine for the pancreatic frozen section examination and diagnosis, wherein the processor can acquire a first frozen section image of the pancreas, acquire a second frozen section image corresponding to the first frozen section image of the pancreas, and generate and provide a diagnosis result for the pancreatic frozen section examination on the basis of the first frozen section image and the second frozen section image by using the artificial intelligence engine.

INFUSION DEVICES AND RELATED METHODS AND SYSTEMS FOR PREEMPTIVE ALERTING

Absstract of: US2025222201A1

Techniques disclosed herein relate to infusion devices and alerts. In some embodiments, the techniques may involve determining an expected glucose measurement value after delivery of a correction bolus based on an amount of the correction bolus and a current amount of active insulin in a body of a patient. The techniques may further involve obtaining a current glucose measurement value. The techniques may further involve detecting an anomalous response to the correction bolus responsive to determining that a difference between the current glucose measurement value and the expected glucose measurement value exceeds a predetermined threshold.

SYSTEMS, DEVICES, AND METHODS FOR WELLNESS MONITORING WITH PHYSIOLOGICAL SENSORS

Absstract of: WO2025146479A1

Systems and methods for monitoring glucose levels of a user are described. Data indicative of glucose levels of the subject is received. A count is assigned for each glucose episode based at least on an area under the curve of the each glucose episode in a dataset of time- correlated glucose data. A running sum of counts for each glucose episode in a time period is calculated. The running sum of the counts may be displayed in a numerator of a fraction and a target count goal in a denominator of the fraction. A progress indicator representative of the running sum of the counts relative to a target count goal for the time period may also be displayed. A length of a variable portion may be proportional to the running sum of the counts, and a total length of the progress indicator may be proportional to the target count goal.

ANALYTE SENSORS AND SENSING METHODS FOR DUAL DETECTION OF GLUCOSE AND ETHANOL

Absstract of: US2025221643A1

Multiple enzymes may be present in one or more active areas of an electrochemical analyte sensor for detecting one or more different analytes. In particular, an analyte sensor may comprise a sensor tail configured for insertion into a tissue and one or more working electrodes having a glucose-responsive active area and an ethanol-responsive active area to detect glucose and ethanol in vivo.

COIN-SIZED, FULLY INTEGRATED AND MINIMALLY INVASIVE CONTINUOUS GLUCOSE MONITORING SYSTEM (CGMs) BASED ON ORGANIC ELECTROCHEMICAL TRANSISTORS

Absstract of: US2025221637A1

This invention provides a coin-sized, fully integrated and wearable continuous glucose monitoring system (CGMs) via combining cutting-edge technologies from the intersecting fields of biosensors, minimally invasive tools, and hydrogels. The invention includes three major parts: 1) an emerging biochemical amplifier, the organic electrochemical transistor (OECT), to improve sensitivity beyond traditional electrochemical modules; 2) a microneedle array for interstitial-fluid (ISF) sampling with reduced pain during skin penetration; and 3) a tough, adhesive enzymatic-hydrogel-membrane to enhance reliability of glucose sensing on skin. Unlike conventional CGMs, the employed OECT amplifier empowers the CGM (OECT-CGMs) with a high anti-noise ability, an on-demand-tunable sensitivity and current regeneration ability, enabling long-term stable glucose sensing within specific clinical ranges (1 ̃20 mM). This work paves the way for the development of next-generation CGMs that can simultaneously deliver high and adjustable sensitivity, minimal invasiveness, and improved wearability.

SYSTEM AND METHOD FOR IMPROVING THE DRUG THERAPY MANAGEMENT

Absstract of: US2025226076A1

An aspect of the invention provides a method and a product for determining a modification of the therapy management by using a processor unit which retrieves few data related to the blood glucose measurement performed over a predetermined time period; retrieve the medication delivery parameter executed by the delivery device over said predetermined time period; retrieve from the memory data associated to the CIR of the patient; and determine a modification to the therapy based on at least a part of the retrieved data.

SYSTEMS, DEVICES, AND METHODS FOR WELLNESS MONITORING WITH PHYSIOLOGICAL SENSORS

Absstract of: US2025221674A1

Systems and methods for monitoring glucose variability in a subject are described. Data indicative of glucose levels of the subject is received from a sensor control device. A first glucose variability metric of the subject in a first time period is determined. The first glucose variability metric may be compared to a threshold. A first indicator is displayed if the first glucose variability metric does not exceed the threshold and a second indicator is displayed if the first glucose variability metric exceeds the threshold. Additional glucose variability metrics may be determined for subsequent time periods according to a rolling window, and the indicators may be displayed real time or in a report. The glucose variability metric may be a measure of variability compared to a baseline, a difference between a maximum and minimum glucose level, or time in or out of a target range.

MULTI-HEAD CONVOLUTIONAL NETWORK FOR AVERAGE GLUCOSE PREDICTION

Absstract of: CN119731745A

Systems and methods for determining a glucose value of a user are disclosed herein. The method includes: receiving a plurality of data inputs associated with biometric data of a user, the plurality of data inputs including at least one data input representing past estimated glucose values of the user; and processing the plurality of data inputs with a multi-head temporal convolutional neural network to generate a blood glucose value for the user. The method further includes providing a notification to the user based at least in part on the blood glucose value.

RF BIOSENSING SYSTEM USING RF SENSOR INCLUDING MICRONEEDLE

Absstract of: WO2025143904A2

Disclosed is an RF biosensing system using an RF sensor including a glucose-responsive hydrogel-based microneedle. The RF biosensing system measures a sensing signal with a VNA by detecting a sensing signal by using a reader antenna and a reader antenna sensing circuit through a readout coil on the basis of RF biosensing and wireless transmission, via EM coupling between a glucose-responsive hydrogel-based microneedle, which is provided below a flexible substrate so as to be minimally invasively applied in vivo to the skin surface (on-site) of epidermis/dermis/hypodermis of the skin or to skin/fat/muscle tissue, and an RF sensor, which is positioned over the flexible substrate and uses the difference in resonant frequencies within frequencies of 400 to 3,000 MHz, and performs biosensing such as detection of proteins, glucose, and fat in the skin, on the basis of changes in the capacitance of a sensing antenna circuit (LC resonator) of the RF sensor, shifts in resonant frequencies of the LC resonator, and changes in S-parameters.

BLOOD GLUCOSE LEVEL MEASUREMENT DEVICE

Absstract of: WO2025141628A1

This blood glucose level measurement device comprises: a sensor unit that measures the blood glucose level of a user; a communication unit that transmits, to the outside, data representing the blood glucose level measured by the sensor unit; a flexible, sheet-shaped battery that supplies power to the sensor unit and the communication unit; a flexible, plate-shaped circuit unit that controls the operation of the communication unit; and a mounting unit that is configured to be mounted on the body of the user. The peak current of the battery is 20 mA or more.

Peritoneal Dialysis System with Sensors and Configured to Diagnose Peritonitis

Absstract of: AU2025204350A1

Peritoneal dialysis, such as automated peritoneal dialysis (“APD”) is provided with any one or more or all of the following sensing or feedback features: impedance sensing to detect peritonitis, temperature sensing to detect peritonitis, bio-MEMS sensing to detect peritonitis, and glucose control for diabetes patients, wherein each sensing or feedback feature analyzes patient effluent fluid or fluid dwelling within a patient’s peritoneal cavity. Peritoneal dialysis, such as automated peritoneal dialysis ("APD") is provided with any one or more or all of the following sensing or feedback features: impedance sensing to detect peritonitis, temperature sensing to detect peritonitis, bio-MEMS sensing to detect peritonitis, and glucose control for diabetes patients, wherein each sensing or feedback feature analyzes patient effluent fluid or fluid dwelling within a patient's peritoneal cavity. un u n e r i t o n e a l d i a l y s i s , s u c h a s a u t o m a t e d p e r i t o n e a l d i a l y s i s ( " " ) i s p r o v i d e d w i t h a n y o n e o r m o r e o r a l l o f t h e f o l l o w i n g s e n s i n g o r f e e d b a c k f e a t u r e s : i m p e d a n c e s e n s i n g t o d e t e c t p e r i t o n i t i s , t e m p e r a t u r e s e n s i n g t o d e t e c t p e r i t o n i t i s , b i o - s e n s i n g t o d e t e c t p e r i t o n i t i s , a n d g l u c o s e c o n t r o l f o r d i a b e t e s p a t i e n t s , w h e r e i n e a c h s e n s i n g o r f e e d b a

WIRED IMPLANTABLE MONOLITHIC INTEGRATED SENSOR CIRCUIT

Absstract of: US2025213146A1

There is provided a glucose sensor system comprising: a transmitter (2) for containing a battery (212), the transmitter being for placement on top of patient skin; a transcutaneous connector (3) comprising at least one conductive path; and an implantable monolithic integrated circuit (I) for placement beneath the patient skin, wherein the implantable monolithic integrated circuit comprises a potentiostat and an electrochemical sensing element; wherein the potentiostat is electrically coupled to the transmitter (2) via the transcutaneous connector (3), and the electrochemical sensing element is configured to sense glucose concentration and generate an electrical signal representative of the glucose concentration, and wherein the potentiostat is electrically connected to the electrochemical sensing element.

SYSTEMS AND METHODS FOR ANALYZING, INTERPRETING, AND ACTING ON CONTINUOUS GLUCOSE MONITORING DATA

Absstract of: US2025213147A1

Methods and devices include automated coaching for management of glucose states by receiving a user's glucose levels using a continuous glucose monitoring (CGM) device, determining a time in range (TIR) value, determining a TIR state, receiving a glucose variability (GV) value, determining a GV state, determining a starting state based on the TIR state and the GV state, determining that the starting state corresponds to a non-ideal state, generating an optimized pathway to reach an ideal state based on one or more account vectors such as addressing self-management behavior including food, activity, and medication use. The optimized pathway may further be based on computer detection and classification of significant events of interest over time.

METHOD AND COMPUTING DEVICE FOR NON-INVASIVELY ESTIMATING BLOOD GLUCOSE, DEVICE FOR NON-INVASIVELY MEASURING ELECTROCARDIOGRAM SIGNAL, AND NON-TRANSITORY COMPUTER READABLE STORAGE MEDIUM

Absstract of: US2025213145A1

A method for non-invasively estimating blood glucose for estimating a blood glucose value of a user by a computing device. The method includes receiving a plurality of electrocardiogram (ECG) waveforms of the user, extracting at least two first ECG features from each of the plurality of ECG waveforms of the user, respectively determining a first feature peak position corresponding to each of the first ECG features, calculating at least one peak distance between the plurality of the first feature peak positions, and estimating the blood glucose value of the user based on the peak distance. The first ECG features are selected from the group consisting of a P-wave, a Q-wave, an R-wave, an S-wave, a T-wave, and a U-wave. Furthermore, a computing device for non-invasively estimating blood glucose, a device for non-invasively measuring ECG signal, and a non-transitory computer readable storage medium are utilized for the method.

GLUCOSE MONITORING METHOD AND SYSTEM

Absstract of: US2025213202A1

This invention provides a system and method to protect an artificial pancreas' sensor, infusion system, and alert systems from EMI/wireless attacks using a medical software or application, close the gap between sensor glucose and blood glucose, and build a non-invasive hypoglycemia and hyperglycemia false alarm detection scheme with the help of a wristband. This inventive method and system provides a more accurate blood glucose prediction. It comprises preprocessing the CGM readings with Kalman smoothing for sensor error correction improves the robustness of the BG prediction. In one or more embodiments, the inventive system and method uses one or more physiological information such as meal, insulin, aggregations of step count, and preprocessed CGM data. The invention provides a novel approach for leveraging the stacked LSTM based deep RNN model to improve the BG prediction accuracy. The invention provides a special circuits-Transduction Shield-to detect and correct the sensor errors caused by EMI attacks.

COMPRESSION EVENT DETECTION AND PREVENTION

Absstract of: US2025213191A1

A continuous analyte monitoring system includes analyte sensors configured to sense analytes such as lactate and glucose in the tissue of a user. A controller is coupled to the analyte sensors and configured evaluate first samples of outputs of a first analyte sensor and second samples of outputs of a second analyte sensor to determine whether the first samples and the second samples indicate compression of the tissue. The controller compensates for the compression of the tissue with respect to the first samples. A force sensor may be used and may be positioned between a circuit board and a housing, the circuit board supported by supports providing preloading of the force sensor. A force deflector may be used to direct loads away from tissue holding the analyte sensors. A housing may have a flexible lower surface to reduce loading of the tissue.

BODY ATTACHABLE UNIT FOR CONTINUOUS BLOOD GLUCOSE MEASUREMENT

Absstract of: US2025213155A1

The present disclosure relates to a body attachment unit for continuous blood glucose measurement, in which the body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work and allowing attachment of the body attachment unit to a body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without performing additional work of connecting a separate transmitter, and allowing easier maintenance. In addition, activation occurs by a user's operation after the body attachment unit is attached to the body, such that an activation start point in time can be adjusted to an appropriate point in time according to the user's needs, and activation occurs in a stabilized state, thereby providing the body attachment unit allowing more accurate blood glucose measurement.

EXTENDED WEAR INFUSION SET WITH INCREASED INSULIN PRESERVATIVE RETENTION

Absstract of: US2025213785A1

Disclosed herein are improved infusion sets that incorporate halogenated siloxane materials within the composition of an infusion set septum. Such configurations maintain the mechanical robustness of using elastomeric materials for a fluidic septum while providing barrier properties that prevent phenolic preservative from being absorbed out of the infusion set. Infusion sets as disclosed herein are particularly suitable for maintaining insulin's anti-microbial effectiveness over extended wear (e.g., 7 days) to maintain performance of the infusion set during extended wear and reduce the risk of insulin aggregate propagation.

Systems and Methods for Enabling and Disabling Insulin Pumps in a Multi-Pump Insulin Pump System

Absstract of: US2025213784A1

Systems and methods are provided for enabling and disabling insulin pumps in a multi-pump insulin pump system. For example, multiple pumps (e.g., patch pumps) may be rotated to deliver insulin to a user. In one example, one patch pump may be worn while another patch pump is charging. Once the battery of the patch pump worn by the user is depleted, a mobile device may cause the enabled pump in operation and worn by the user to send the latest pump settings and configuration data to the mobile device which will share the information with the disabled pump. The disabled pump will then update the pump settings based on this information and the mobile device may active the pump such that is now enabled for insulin delivery. The mobile device may also facilitate pairing between the patch pumps and a CGM device as they enabled for use and disabled.

MINIMALLY INVASIVE GLUCOSE FORECASTING SYSTEMS, DEVICES, AND METHODS

Absstract of: US2025218600A1

Glucose forecasting systems and methods that include a minimally invasive scalp-worn behind-the-ear EEG device that includes first and second sensors. With an application on a personal device, analyzing the processed EEG signals with a trained forecasting model and forecasting future glucose levels, of the subject; causing the personal device to visually present on a display information that is indicative of the forecasted future glucose levels.

LIFESTYLE IMPROVEMENT ASSISTANCE SYSTEM AND LIFESTYLE IMPROVEMENT ASSISTANCE PROGRAM

Absstract of: US2025218565A1

The present disclosure provides a technology capable of appropriately supporting improvement of an individual's lifestyle. The lifestyle improvement support system is provided with an acquisition device capable of acquiring from a target person at least their blood glucose level data, physical activity data, and dietary activity data, as well as a controlling device.

SYSTEMS AND METHODS FOR CONTINUOUS GLUCOSE MONITORING OUTCOME PREDICTIONS

Absstract of: US2025218598A1

Methods and devices include predicting future glucose and engagement levels for a user by receiving the user's glucose levels collected by a continuous glucose monitoring (CGM) device over a time period, receiving engagement data associated with the user, wherein the engagement data are associated with the user's medication intake, diet, physical activity, laboratory results, and education activity, determining a first glycemia risk index (GRI) value, determining, using a machine learning model and responsive to the user's glucose levels and the engagement data collected over the time period, one or more predictions for future glucose levels for the user including a prediction that a future GRI value is greater than or less than the first GRI value, and determining, using the machine learning model and responsive to the user's engagement data collected over the time period, one or more predictions for future engagement levels.

MEASUREMENT METHOD, SYSTEM, AND RELATED APPARATUS

Nº publicación: WO2025140653A1 03/07/2025

Applicant:

HUAWEI TECH CO LTD [CN]
\u534E\u4E3A\u6280\u672F\u6709\u9650\u516C\u53F8

Absstract of: WO2025140653A1

The present application discloses a measurement method, a system, and a related apparatus. The method is applied to a first electronic device, wherein the first electronic device comprises a first electrode set and a second electrode set; the distance between the first electrode set and the second electrode set is greater than a first distance; and under the condition that the first electrode set and the second electrode set are implanted into subcutaneous tissue, the method comprises: determining a first physiological parameter by means of the first electrode set; and determining an electrocardiogram signal by means of the first electrode set and the second electrode set. In this way, an electrocardiogram signal of a user can be acquired by the first electronic device anytime and anywhere, and any one or more of other physiological parameters (such as blood glucose, blood ketone, blood lactate, and uric acid) of the user can also be measured, thereby improving the health monitoring efficiency.